

Date of preparation: 26 February 2024

Issuer's abbreviated name: SYNEKTIK SA

Current report: 14/2024 ESPI

Subject: Information on the conclusion of a significant agreement on the sale of a robotic system

Legal basis: Article 17 Section 1 of MAR – confidential information

Body of the report:

Time of publication: 08:54 a.m.

The Management Board of Synektik SA (Company) reports that the Company has concluded a significant agreement with Uniwersytecki Szpital Dziecięcy w Krakowie [University Children's Hospital in Cracow] with its registered office at ul. Wielicka 265, 30-663 Kraków (Hospital).

This agreement pertains to the supply, assembly, installation and commissioning of the da Vinci robotic surgery system for the Hospital along with accompanying equipment, staff training and maintenance care. This agreement was concluded as a result of a public tender proceeding conducted in the form of an unlimited tender for the net amount of PLN 13,504,361.13.

The da Vinci system will be delivered within a term of up to 5 weeks from the date of signing the agreement. The warranty period for system delivery is 24 months from signing the final acceptance report.

The other clauses in the agreement concluded by the Company do not deviate from the standards generally used in contracts of this type.

The signing of this agreement was deemed to be significant by the Management Board of Synektik SA since its net value exceeds 5% of the equity of the Synektik Group disclosed in its last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting

standards. The proceeds generated by executing this project will affect the sales results in the 2023 financial year lasting from 1 October 2023 to 30 September 2024.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board